Log in to save to my catalogue

Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cell...

Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cell...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2675604847

Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275)

About this item

Full title

Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275)

Publisher

New York: Springer US

Journal title

Medical oncology (Northwood, London, England), 2022-06, Vol.39 (8), p.119-119, Article 119

Language

English

Formats

Publication information

Publisher

New York: Springer US

More information

Scope and Contents

Contents

Circulating tumor cells detection and ARV7 expression are associated with worse clinical outcomes in metastatic Castration-Resistant Prostate Cancer (mCRPC) undergoing Androgen Receptor Targeted Agents. ARFL, PSMA and PSA may help to refine prognostic models. In our institution, a prospective observational trial testing CTC detection in mCPRC under...

Alternative Titles

Full title

Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2675604847

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2675604847

Other Identifiers

ISSN

1559-131X,1357-0560

E-ISSN

1559-131X

DOI

10.1007/s12032-022-01756-2

How to access this item